about
Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-AnalysisContinuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies.Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study.Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.Insulin analogues in type 1 diabetes mellitus: getting better all the time.Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease.Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.Differential Treatment Response to Insulin Intensification Therapy: A Post Hoc Analysis of a Randomized Trial Comparing Premixed and Basal-Bolus Insulin Regimens.Perspectives on Peripheral Neuropathy as a Consequence of Metformin-Induced Vitamin B12 Deficiency in T2DM.Impact of diabetes in the Friedreich ataxia clinical outcome measures study.Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney functionLifestyle Medicine: A Brief Review of Its Dramatic Impact on Health and SurvivalCombination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus.Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus.Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies.Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study.Semaglutide-the "new kid on the block" in the field of glucagon-like peptide-1 receptor agonists?Correlates of second-line type 2 diabetes medication selection in the USA.Monotherapy in Patients with Type 2 Diabetes Mellitus.The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis.Monotherapy in patients with type 2 diabetes mellitus.Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study.Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial.Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03).Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.Macrocarpal C isolated from Eucalyptus globulus inhibits dipeptidyl peptidase 4 in an aggregated form.Latent autoimmune diabetes of adulthood: case report.Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus.Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.
P2860
Q33732588-54C15774-4B29-4458-97DA-E7106A3C09C3Q33732649-5BB6B3C4-11F2-4017-B1F0-40151CB34F8CQ33786220-42E6D5F7-52C3-4966-8BEF-CE58D1DF6BE1Q33814995-5421FAFC-269C-4844-A834-A62ED8E33DDAQ36406404-F22DC723-BF7E-42F6-BF15-2FB48917F773Q38640170-C05E2F1C-2CD1-4DCA-9AA9-6A7024BAB06EQ38692387-43AD5502-C2D8-442C-8872-81FF19EBA03AQ38836120-CF8111F8-E96F-43A3-B7AE-7D278C5EABD8Q39152332-AF846074-2C2F-4296-9535-7ADD4CDE8FFCQ39255188-5301BCE9-8E8D-484C-BCCB-0BB32889D872Q39420208-4FE8C526-08B1-4A0E-9C3C-8ECC58EED966Q40225979-3190653E-3EAC-4099-B9F9-DBE3B6E50A6EQ41176211-A59499A0-511C-437B-91E9-F488E35B2D3CQ41259514-7343A827-2F66-493C-9F80-71B70157B2A9Q41448734-2E68A0CE-7708-43E9-95BA-D3C6D614654FQ41509984-DD4C4AE4-6AD8-4BD7-A855-A1518B34926DQ42206175-751BBB1C-4885-4DE4-B158-60DCD87FC0BFQ42281416-1C33B9A9-F873-4C6C-9312-2C1EB84F01B6Q42375892-2CE82E8A-2793-47FC-A6A4-8C1A3D7A57C5Q46087999-5EFE171D-323B-47FF-A8F7-E52597E661B3Q46184005-596CE439-ED09-47B6-8E9E-E105AD87E8BDQ46348934-B43EA77D-F959-4E2F-93BA-906734827BF0Q46505421-7A990C24-A672-484A-858C-4C1656FBD671Q46780181-3E43410E-3F6D-414E-ADD2-73514BD0885BQ47097015-619DDF23-881D-4267-AB8D-FE8E35271838Q47102145-80E4C664-A726-4F74-BA20-0A37BFC94A4CQ47110030-E060043D-014D-45DD-8256-34A33892A93CQ47117670-74B1191C-5A4A-45EB-891C-34C1A69B5325Q47123503-EA68003D-560C-46D7-BAD3-42930FFE4B56Q47139956-61545154-A0D2-467E-9645-705A12CC2E23Q47154668-72CEF644-8A7D-4413-9067-DC641D7B20DBQ47172963-9F46C554-B423-4E48-981F-9DD6D4200EC5Q47246352-1D65F8F3-8294-479D-883A-528A2D7A501CQ47263832-2918FB66-7E76-4A6F-A5D3-3CBD8EAFB341Q47293312-FB9E337B-2D5C-483E-9AED-DBF40BD7E2AAQ47367638-41348ED1-31A1-46D6-AA32-2416F23C4C77Q47392659-0BCE46A1-7647-4096-9A42-E655289650DAQ47568289-8C205619-FA3E-484C-B242-B7BA2A13C3D4Q47672213-46075A56-911E-475F-89E9-18018CDAD675Q47722005-DF083F28-3A43-4724-9430-1B1E6475B47D
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
8. Pharmacologic Approaches to Glycemic Treatment.
@en
8. Pharmacologic Approaches to Glycemic Treatment.
@nl
type
label
8. Pharmacologic Approaches to Glycemic Treatment.
@en
8. Pharmacologic Approaches to Glycemic Treatment.
@nl
prefLabel
8. Pharmacologic Approaches to Glycemic Treatment.
@en
8. Pharmacologic Approaches to Glycemic Treatment.
@nl
P356
P1433
P1476
8. Pharmacologic Approaches to Glycemic Treatment.
@en
P304
P356
10.2337/DC17-S011
P407
P433
P577
2017-01-01T00:00:00Z